An observational study in Coronary Artery Disease, sponsored by Young-Hak Kim, MD, PhD. Completed at 13 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-03-22.
Sponsored by Young-Hak Kim, MD, PhD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.
Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 77th largest by enrollment of the 152 observational ones that give a count, is one of 18 that started in 2013, is one of 153 observational ones, and was the 101st registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+
Jung-min Ahn · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 20+
Bon-Kwon Koo · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
361 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 15 · Phase 4 95
First in 2003; this study’s year is marked. 18 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,059 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 472 across the 208 interventional studies, 1,113 across the 152 observational. Of the 199 that completed or were terminated, 14 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 361 have an industry lead sponsor. The 10 most frequent:
Young-Hak Kim, MD, PhD is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Young-Hak Kim, MD, PhD has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Coronary Artery Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02792075Seung-Jung ParkPrognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study | 2026-12 |
| NCT05340361Yonsei UniversityEfficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT | 2026-12-31 |
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT02038660Seung-Jung ParkDrug-Eluting Balloon Registry in Routine Clinical Practice | 2026-12-31 |
| NCT06066450Genoss Co., Ltd.Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether coronary perfusion computed tomography is effective in the treatment of coronary artery disease.
General hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Accuracy of coronary perfusion computed tomography
Positive predictive value Negative predictive value Sensitivity Specificity
Time frame: 5year
Relationship between coronary perfusion computed tomography and fraction flow reserve
Time frame: 5year
Relationship between coronary perfusion computed tomography and SPECT(nuclear imaging)
Time frame: 5year
occurrence of the event after coronary perfusion computed tomography
Death Myocardial infarction coronary angiography Revascularization
Time frame: 5year
Ran from Nov 2013 to primary completion in Nov 2020, 84 months.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 84 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Young-Hak Kim, MD, PhD